All In Biotech

Drug Trial Radar · NCT06600841

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer

Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in the Treatment of Patients with Recurrent Platinum-resistant Ovarian Cancer (Sunrise Trial): a Single-Arm, Exploratory Study

Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

37

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Mar 1, 2026

Study completion Oct 1, 2028

Sponsor

Lead sponsor
Fujian Cancer HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Fujian Provincial Hospital
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The investigators explore the efficacy and safety of adebrelimab (PD-L1 inhibitor) plus Non-platinum chemotherapy and Fuzuloparib (PARP inhibitor) induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib in platinum-resistant relapsed/metastatic ovarian cancer.

Conditions

  • Platinum-resistant Ovarian Cancer (PROC)
  • Immunotherapy

Interventions

  • Immunotherapy(Adebrelimab)Drug

    Adebrelimab plus non-platinum chemotherapy(Liposomal doxorubicin/Gemcitabine/ or nab-paclitaxel)and fluzoparib induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib.

  • immunotherapy(Adebrelimab)Drug

    anti-PD-L1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate(ORR)Time frame: From the enrollment to the final documentation of response of the last subject (assessed up to 36 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.